PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
41.18%
R&D change of 41.18% while AGEN maintains spending. Bruce Berkowitz would investigate effectiveness.
22.12%
G&A growth above 1.5x AGEN's 11.94%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.03%
Operating expenses growth above 1.5x AGEN's 14.49%. Michael Burry would check for inefficiency.
35.03%
Total costs growth above 1.5x AGEN's 3.51%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
14.84%
Similar D&A growth to AGEN's 16.04%. Walter Schloss would investigate industry patterns.
-35.35%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-35.03%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.72%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-37.55%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.55%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-34.88%
EPS decline while AGEN shows 95.07% growth. Joel Greenblatt would examine position.
-34.88%
Diluted EPS decline while AGEN shows 95.15% growth. Joel Greenblatt would examine position.
2.03%
Share count reduction exceeding 1.5x AGEN's 2078.15%. David Dodd would verify capital allocation.
2.03%
Diluted share reduction exceeding 1.5x AGEN's 2116.20%. David Dodd would verify capital allocation.